KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Inventory: 2017-2024

Historic Inventory for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $6.0 million.

  • Aquestive Therapeutics' Inventory rose 12.29% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year increase of 12.29%. This contributed to the annual value of $6.0 million for FY2024, which is 10.71% down from last year.
  • As of FY2024, Aquestive Therapeutics' Inventory stood at $6.0 million, which was down 10.71% from $6.8 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Inventory high stood at $6.8 million for FY2023, and its period low was $2.5 million during FY2020.
  • Over the past 3 years, Aquestive Therapeutics' median Inventory value was $6.0 million (recorded in 2024), while the average stood at $6.2 million.
  • In the last 5 years, Aquestive Therapeutics' Inventory declined by 13.92% in 2020 and then spiked by 64.08% in 2021.
  • Aquestive Therapeutics' Inventory (Yearly) stood at $2.5 million in 2020, then soared by 64.08% to $4.0 million in 2021, then soared by 43.14% to $5.8 million in 2022, then climbed by 17.11% to $6.8 million in 2023, then fell by 10.71% to $6.0 million in 2024.